The Swiss pharmaceutical company has set a high bar for any potential obesity-treatment acquisition as it scans the market ...
Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...
Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...
Amgen’s mysterious obesity asset will remain a mystery for a bit longer—the FDA has put the candidate’s phase 1 trial ...
Wegovy maker Novo Nordisk on Wednesday forecast slower sales growth for 2025 than 2024, a blow that is likely to deepen ...
Telehealth company Hims & Hers' first Super Bowl ad is provocative and effective in building awareness of its weight loss ...
The economic burden of obesity is also significant. In the Finger Lakes, excess medical spending due to obesity is estimated ...
Sales of Novo Nordisk’s obesity drug, Wegovy, rose by more than 50 per cent last year, helping the Danish drugmaker beat revenue expectations.
The company said the agency's hold was "not related to the drug,” dubbed AMG 513, and that discussions were underway to ...
Canadian youngsters are munching loads of ultra-processed foods, increasing their lifelong risk of obesity, a new study says.
Danish pharmaceutical behemoth Novo Nordisk reported better-than-expected net profit in the fourth quarter, amid soaring demand for its Wegovy obesity drugs.